Latest Ratios: P/E Ratio 10.4x · EV/EBITDA N/A · ROE 85.7%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $828M | $513M | $386M | $232M | $158M | $259M | $45M | $11M | $32M | $59M | $43M |
| Enterprise Value | $829M | $514M | $412M | $233M | $112M | $149M | $111M | $88M | $96M | $142M | $118M |
| P/E Ratio → | 10.38 | 6.64 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 7.78 | 4.82 | 16.34 | 8.46 | 15.58 | 9.05 | 3.36 | 0.88 | — | — | — |
| P/B Ratio | 5.19 | 3.32 | 9.72 | 3.75 | 2.11 | 2.04 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | 25.08 | — | — | — | — | — |
| P/OCF | — | — | — | — | — | 24.84 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.83 | 17.46 | 8.48 | 10.98 | 5.18 | 8.35 | 6.82 | — | — | — |
| EV / EBITDA | — | — | — | — | — | 18.60 | — | — | — | — | — |
| EV / EBIT | — | 5.43 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | 14.37 | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.5% | 84.5% | 68.6% | 89.3% | 97.8% | 92.8% | 90.2% | 77.1% | — | — | — |
| Operating Margin | -4.0% | -4.0% | -368.5% | -180.6% | -418.9% | 27.0% | -42.2% | -158.4% | — | — | — |
| Net Profit Margin | 78.2% | 78.2% | -446.9% | -167.7% | -263.5% | -29.9% | -96.0% | -191.0% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 85.7% | 85.7% | -207.8% | -67.2% | -26.5% | -28.2% | — | — | — | — | — |
| ROA | 36.0% | 36.0% | -60.2% | -32.0% | -21.6% | -11.9% | -117.5% | -131.7% | -142.6% | -63.2% | -23.5% |
| ROIC | -2.9% | -2.9% | -101.4% | -81.8% | -142.5% | 71.1% | -473.5% | -822.3% | -378.3% | -61.3% | -151.2% |
| ROCE | -2.2% | -2.2% | -71.7% | -49.1% | -36.7% | 11.7% | -128.2% | -205.2% | -200.8% | -56.0% | -59.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.41 | 0.41 | 1.52 | 0.71 | 0.25 | 0.01 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 0.20 | — | — | — | — | — |
| Net Debt / Equity | — | 0.01 | 0.67 | 0.01 | -0.62 | -0.87 | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | -13.87 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -10.71 | — | — | — | — | — |
| Interest Coverage | 11.87 | 11.87 | -11.26 | -29.68 | -79.01 | -21.66 | -0.80 | -2.77 | -7.66 | -4.55 | -4.84 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.68 | 5.68 | 2.53 | 1.18 | 7.72 | 27.20 | 1.11 | 1.28 | 1.98 | 3.99 | 11.19 |
| Quick Ratio | 5.63 | 5.63 | 2.47 | 0.85 | 7.72 | 27.20 | 1.11 | 1.28 | 1.98 | 3.99 | 11.03 |
| Cash Ratio | 4.86 | 4.86 | 2.04 | 0.92 | 6.89 | 26.56 | 0.56 | 0.59 | 1.81 | 3.67 | 10.20 |
| Asset Turnover | — | 0.37 | 0.13 | 0.16 | 0.09 | 0.22 | 1.19 | 1.22 | — | — | — |
| Inventory Turnover | 9.47 | 9.47 | 3.76 | 0.12 | — | — | — | — | — | — | 0.16 |
| Days Sales Outstanding | — | 79.73 | 162.45 | 230.97 | 298.11 | 19.47 | 70.84 | 53.02 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 9.6% | 15.1% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | 4.0% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 1.5% | 3.0% | 1.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 1.5% | 3.0% | 1.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $57M | $46M | $35M | $34M | $30M | $4M | $2M | $1M | $915806 | $912315 |
Commercial launch execution risk
Based on recent financial data, ZVRA trades at a P/S ratio of 7.51, which appears to discount the company relative to larger orphan drug peers, suggesting the market remains skeptical of the firm's ability to independently scale its commercial infrastructure for the newly launched MIPLYFFA product.
The current P/E of 10.01 is likely distorted by non-recurring accounting gains, making it a poor proxy for future earnings power. Investors should instead focus on the forward P/E of 12.69, which implies that the market is pricing in a significant ramp in commercial revenue while simultaneously applying a discount for the inherent risks of a small-cap biotech transitioning to a direct-sales model.
As reported in quarterly filings, ZVRA's ROIC reached 29.3% in 2026Q1, a sharp reversal from the -54.0% observed in 2025Q2, indicating that the company's ability to compound capital is currently driven by accounting volatility rather than consistent operational efficiency or sustainable margin expansion.
The extreme fluctuations in ROIC suggest that the company has not yet achieved a stable return profile, as the metric is heavily influenced by the timing of milestone payments and acquisition-related accounting. Analysts should monitor whether the company can maintain positive returns on capital as it shifts away from royalty-heavy income toward the more capital-intensive direct commercialization of its rare disease portfolio.
According to recent financial statements, ZVRA's asset turnover remains low at 0.13, reflecting the company's transition from an IP-focused royalty model to a commercial entity that must now manage the complexities of inventory and distribution for its rare disease therapeutic offerings.
The high days inventory outstanding (DIO) of 96 days in 2026Q1 warrants further investigation, as it may indicate early-stage challenges in aligning supply chain logistics with actual patient demand. Investors should monitor the cash conversion cycle closely, as any persistent inefficiency in working capital management could pressure the company's liquidity during the critical launch phase of its lead assets.
Based on 2026Q1 reported figures, ZVRA maintains a current ratio of 4.89, which represents a significant improvement from the 1.18 ratio seen in 2023Q4, providing the firm with a necessary liquidity cushion to navigate the high fixed-cost environment of its specialized rare disease sales force.
The strong current ratio suggests that the company is well-positioned to meet its short-term obligations without immediate reliance on dilutive capital raises. However, because this liquidity is partially tied to inventory and receivables, investors should assess whether this buffer would hold under a scenario where the commercial launch of MIPLYFFA faces slower-than-expected adoption rates.
As indicated by the 2026Q1 net margin of 104.6%, investors should be wary of using this metric to gauge profitability, as it is heavily inflated by non-recurring items that do not reflect the underlying economics of the company's commercial-stage rare disease business model.
The net margin is frequently misapplied by analysts who fail to strip out bargain purchase gains and milestone-related accounting, which creates a false sense of operational maturity. A more accurate assessment of the company's earning power requires focusing on the gap between gross profit and operating expenses, which better captures the true cost of the commercial infrastructure being built.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ZVRA stock.
Zevra Therapeutics, Inc.'s current P/E ratio is 10.4x. The historical average is 6.6x. This places it at the 100th percentile of its historical range.
Zevra Therapeutics, Inc.'s return on equity (ROE) is 85.7%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -48.8%.
Based on historical data, Zevra Therapeutics, Inc. is trading at a P/E of 10.4x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Zevra Therapeutics, Inc. has 84.5% gross margin and -4.0% operating margin.